IP Library › Granted Patent US 8,633,178
Granted Patent B2
US 8,633,178 · App. 13/684,002 · Granted Jan 21, 2014

Natural combination hormone replacement formulations and therapies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,633,178
App. No.
13/684,002
Granted
Jan 21, 2014
Kind
B2
Abstract

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

Claims (9)

1. A pharmaceutical formulation comprising solubilized estradiol, suspended progesterone, and a medium chain solubilizing agent;

wherein each of the estradiol and the suspended progesterone are present in the solubilizing agent and the estradiol and the suspended progesterone are uniformly dispersed;

wherein at least about 90% of the estradiol is solubilized in the solubilizing agent; and

wherein the solubilizing agent comprises a C6-C12 oil.

2. The pharmaceutical formulation of claim 1 , further comprising partially solubilized progesterone.

3. The pharmaceutical formulation of claim 1 , wherein the formulation is contained within a gelatin capsule.

4. The pharmaceutical formulation of claim 1 , wherein the medium chain solubilizing agent is selected from at least one of mono-, di-, and triglycerides and combinations thereof.

5. The pharmaceutical formulation of claim 1 , wherein said estrogen has a dosage strength at least about 0.125 mg and wherein said progesterone has a dosage strength at least about 25 mg.

6. The pharmaceutical formulation of claim 1 , wherein the ratio of progesterone to estradiol is at least 95:1.

Assignments (9)
TERMINATION AND RELEASE OF GRANT OF A SECURITY INTEREST - PATENTS Recorded Dec 30, 2022
From: SIXTH STREET SPECIALTY LENDING, INC. (F/K/A TPG SPECIALTY LENDING, INC.)
To: THERAPEUTICSMD, INC.
Reel/Frame 062254/0813 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO. 16/401,844 PREVIOUSLY RECORDED AT REEL: 050928 FRAME: 0987. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF ADDRESS. Recorded Sep 24, 2021
From: THERAPEUTICSMC, INC.
To: THERAPEUTICSMD, INC.
Reel/Frame 057698/0571 →
SECURITY INTEREST Recorded Sep 18, 2020
From: THERAPEUTICSMD, INC.
To: SIXTH STREET SPECIALTY LENDING, INC. (F/K/A TPG SPECIALTY LENDING, INC.)
Reel/Frame 053820/0001 →
CHANGE OF ADDRESS Recorded Nov 5, 2019
From: THERAPEUTICSMD, INC.
To: THERAPEUTICSMD, INC.
Reel/Frame 050928/0987 →
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2019
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: THERAPEUTICSMD, INC.; VITAMEDMD, LLC; BOCAGREENMD, INC.; VITACARE PRESCRIPTION SERVICES, INC.
Reel/Frame 049012/0215 →
PATENT SECURITY AGREEMENT Recorded Apr 24, 2019
From: THERAPEUTICSMD, INC.
To: TPG SPECIALTY LENDING, INC.
Reel/Frame 048990/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2019
From: SANCILIO, FREDERICK D.
To: THERAPEUTICSMD, INC.
Reel/Frame 048374/0549 →
SECURITY INTEREST Recorded May 2, 2018
From: THERAPEUTICSMD, INC.; VITAMEDMD, LLC; BOCAGREENMD, INC.; VITACARE PRESCRIPTION SERVICES, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 046053/0723 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SUPPORTING LEGAL DOCUMENTATION AS ORIGINALLY SUBMITTED. THE CORRECTED SUPPORTING LEGAL DOCUMENTATION IS ATTACHED. PREVIOUSLY RECORDED ON REEL 030215 FRAME 0024. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 1, 2013
From: BERNICK, BRIAN A.; CACACE, JANICE LOUISE; PERSICANER, PETER H.R.; IRANI, NEDA; AMADIO, JULIA M.
To: THERAPEUTICSMD, INC.
Reel/Frame 030744/0849 →